Johnson & Johnson (JNJ) submitted abiologics license application (BLA) to the FDA seeking approval for nipocalimab, its investigational neonatal Fc receptor (FcRn) blocker, in generalized myasthenia gravis (gMG) indication.The FDA filing is supported by data from the phase III Vivacity-MG3 study, which evaluated nipocalimab in adults with gMG, including those with anti-AChR, anti-MuSK and anti-LRP4 positive antibodies. Data from the study showed that patients who received nipocalimab plus standard of care ( ...

In addition to profiting from ordinary trading activities, the stock market offers opportunities for investors seeking passive income through dividend payouts. Notably, some stocks are set up to reward shareholders regularly. As the markets look ahead to 2025, several stocks can be tapped to offer passive income. Some of these companies have a history of stable dividends and consistent growth.Therefore, below are three stocks to consider for a dividend-focused portfolio in 2025. Johnson & Johnson (NYSE: JNJ ...

CHINA - 2024/07/27: In this photo illustration, Johnson & Johnson logo is displayed on a smartphone ... [+] with a laptop keyboard background. (Photo Illustration by Serene Lee/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesIf you are a Johnson & Johnson investor and have been enjoying the stock’s steady dividends, it may be time to look elsewhere. As of this moment, we find DaVita - a healthcare company focused on kidney dialysis services - and Duke Energy - an electric an ...

Johnson & Johnson JNJ has just made a significant technical move, achieving a Golden Cross. This technical pattern occurs when a stock’s short-term moving average crosses above its long-term moving average, indicating a potential shift from a bearish to a bullish trend. Chart created using Benzinga ProFor Johnson & Johnson, the stock’s 50-day simple moving average (SMA) of $155.36 has crossed above the 200-day SMA of $154.46, signaling strong upward momentum.Golden Cross: What It Means For Johnson & Johnson ...

Marks first FDA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce levels of autoantibodies  Filing based on the Phase 3 Vivacity-MG3 program, the first-and-only study results in the class demonstrating sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+SPRING HOUSE, Pa., Aug. 29, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the submission of a Biolog ...

文章核心观点 - J&J的股票在过去3个月内上涨12.8%,优于行业11.4%的涨幅,也超过了大盘[1][2] - J&J的创新药业务表现强劲,有望在2025年前实现600亿美元的销售目标[6][7] - J&J面临着持续的法律纠纷,主要涉及其止痒产品中含有石棉导致女性患上卵巢癌的指控[9][10] - J&J的医疗器械业务在中国市场增长放缓,部分抵消了整体业务的增长[12][13] - J&J的估值相对行业较低,但未来增长预期有所下调[14][26][27] 公司概况 - J&J是一家高度多元化的制药公司,拥有超过275家子公司[6] - J&J在2023年8月将消费者健康业务分拆为独立上市公司Kenvue[6] - J&J的创新药业务是公司的主要增长引擎,有10款新药有望在未来实现50亿美元以上的峰值销售[7][8] 业务表现 - J&J的创新药业务连续13年实现高于市场的增长,预计未来5年内将保持5%-7%的增速[7] - J&J的医疗器械业务在中国市场受到政策影响和竞争压力的影响,导致增长低于预期[12][13] - J&J面临Stelara专利到期的挑战,未来销售和利润可能受到生物类似药的冲击[11] 风险因素 - J&J持续面临大量与止痒产品相关的诉讼,已有超过6.2万起诉讼[9][10] - J&J的法律纠纷给公司带来了巨大的财务压力,未来几个季度可能继续产生数十亿美元的法律费用[28]

Johnson & Johnson (JNJ) announced that the European Commission (EC) has approved its lung cancer drug Rybrevant (amivantamab) for expanded use.The EC approved a type II extension of indication for Rybrevant in combination with chemotherapy (carboplatin and pemetrexed) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions after failure of prior therapy, including an EGFR tyrosine kinase inhibitor (TKI).JNJ's Stock PerformanceShares of JNJ have increa ...

IRVINE, CALIFORNIA - OCTOBER 17: The Johnson & Johnson logo is displayed at company offices on ... [+] October 17, 2023 in Irvine, California. Johnson & Johnson beat Wall Street’s quarterly revenue and earnings estimates as sales in its pharmaceutical and medical devices businesses grew. (Photo by Mario Tama/Getty Images)Getty ImagesWe believe that Johnson & Johnson stock (NYSE: JNJ) is currently a better pick than Procter & Gamble stock (NYSE: PG) as it appears to show more promise over the coming years. T ...

文章核心观点 - 欧洲委员会批准了强生公司的药物Balversa(erdafitinib),用于治疗不可切除或转移性尿路上皮癌(UC),该癌症携带易感的FGFR3基因突变 [1][2][3] - Balversa获批适用于之前接受过至少一线PD-1或PD-L1抑制剂治疗的转移性UC患者 [2] - UC是最常见的膀胱癌类型,欧洲是全球膀胱癌发病率最高的地区,约20%的转移性UC患者有FGFR基因突变,此前治疗选择有限 [3] 药物审批情况 - Balversa于2019年获FDA加速批准用于FGFR基因改变的局部晚期或转移性UC,今年1月获得FDA正式批准 [5] - 欧洲批准是基于THOR III期临床试验结果,该试验达到了总生存期主要终点,Balversa组患者中位总生存期超过1年,相比化疗组降低36%死亡风险 [4] 其他临床研究 - 强生公司正在评估Balversa在多项膀胱癌患者中的其他临床研究 [6] 同类公司表现 - 强生公司股价今年迄今上涨4.7%,而行业整体上涨27.4% [3] - 罗氏、阿克图斯和礼来等公司股价和业绩表现较好 [8][9][10][11][12]

These stocks have quality businesses behind them.Some investors might be feeling the brunt of stock market volatility as concerns about inflation persist. The last several years have been a bumpy ride, that's for certain.If you're focused on the long term, you should be holding stocks of great companies that can weather the storm. You should hang on to them for several years at minimum but more likely a decade or more. And if you're only putting your cash into quality companies that you're comfortable with ...